Clinical Research Directory

Inclusion Criteria: * Age 18 years or older * Written informed consent * Has a diagnosis of relapsed and refractory multiple myeloma * Has already received at least three previous treatments * Is refractory to at least 1 proteasome inhibitor, at least 1 immunomodulatory agent, and an anti-CD38 monoclonal antibody * Evidence of disease progression on the last line of therapy, based on determination of response by the IMWG response criteria * Anticipated to start treatment with teclistamab per routine clinical care or has started with teclistamab treatment ≤14 days before intended screening visit Exclusion Criteria: * Has participated in a teclistamab trial (teclistamab or control arm) or teclistamab Single Patient Request (SPR) program * Has started teclistamab treatment \>14 days before intended screening visit.